BioMarin Pharmaceutical (BMRN)
(Delayed Data from NSDQ)
$80.69 USD
-0.16 (-0.20%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $80.80 +0.11 (0.14%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth C Momentum D VGM
Brokerage Reports
BioMarin Pharmaceutical Inc. [BMRN]
Reports for Purchase
Showing records 781 - 800 ( 814 total )
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Kuvan Highlighted in Presentations at ACMG Medical Conference
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
4Q10 and FY10 Financial Results in Line-Introducing Adjusted EBITDA
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: BERNARDINO V
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Q4 Financials: Annual Growth Intact Despite Quarterly Choppiness
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of February 6
Provider: WEDBUSH SECURITIES INC.
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Next Wave of Pipeline Products Enter Clinic
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: BERNARDINO V
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
LIFE SCIENCES -The Week Ahead in Life Sciences - Upcoming Events for the Week of January 16
Provider: WEDBUSH SECURITIES INC.
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
2011 Major Value Drivers in Emerging Pharmaceuticals.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
BMN 673 Approved For Clinical Trial Testing In The UK
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Q3 Financials: Revenues A Bit Light. 2010 Guidance Tightened. We See 2011 As A Potential Inflection With Multiple Catalysts
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Q3 Preview: We See An In-Line Q3 With A Substantial One-Time Tax Benefit
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Initiating Coverage with a Neutral Rating and 12-Month Price Target of $26
Provider: DAWSON JAMES SECURITIES, INC.